HRT Financial’s Humacyte Inc Warrant HUMAW Stock Holding History

HRT Financial’s Portfolio HUMAW Stock Details HUMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,195	Closed	-$14K	–	2807
2023 Q1	$14K	Sell	24,195 -10,949	-31%	-$6.53K	﹤0.01%	2219
2022 Q4	$13K	Sell	35,144 -7,568	-18%	-$6.69K	﹤0.01%	2201
2022 Q3	$49K	Sell	42,712 -3,825	-8%	-$4.22K	﹤0.01%	2447
2022 Q2	$41K	Sell	46,537 -3,713	-7%	-$5.7K	﹤0.01%	2532
2022 Q1	$96K	Sell	50,250 -3,024	-6%	-$5.11K	﹤0.01%	2670
2021 Q4	$121K	Sell	53,274 -910	-2%	-$2.66K	﹤0.01%	2705
2021 Q3	$160K	Buy	+54,184	New	+$159K	﹤0.01%	2762

Other funds holding HUMAW

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

HRT Financial's HUMAW Position: Q2 2023 in Review

HRT Financial sold out of Humacyte Inc Warrant (HUMAW) in Q2 2023, closing a stake of 24,195 shares — an estimated $14K sold.

HRT Financial first reported a position in HUMAW in Q3 2021 and held it in 7 quarters. The position peaked at $160K in Q3 2021. 8 funds tracked by Wall St. Rank hold HUMAW as of Q2 2023.

HRT Financial reported no remaining Humacyte Inc Warrant position as of Q2 2023 after selling out during the quarter.
HRT Financial sold 24,195 Humacyte Inc Warrant shares in Q2 2023, an estimated $14K.
HRT Financial first reported a position in Humacyte Inc Warrant in Q3 2021 and held it in 7 quarters.
HRT Financial's Humacyte Inc Warrant position peaked at $160K in Q3 2021.
8 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.